Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of multiple doses of AFQ056 in
patients with Fragile X Syndrome. The dose range will be 50 to 150 mg b.i.d. The primary
read-out of efficacy is reduction in Aberrant-Behavior Checklist score.